文献速递白血病造血干细胞移植与细胞治疗

ELIANA试验中替沙基仑赛治疗儿童及年轻成人复发/难治性急性淋巴细胞白血病的三年更新

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
PubMed 文献 · J Clin Oncol · 2022-11-18

ELIANA II期试验更新报告79例复发/难治性B细胞急性淋巴细胞白血病儿童及年轻成人患者,中位随访38.8个月,总缓解率82%,中位无事件生存期24个月,中位总生存期未达到,3年总生存率63%,未报告新的长期不良事件,患者报告生活质量改善持续至输注后36个月。

要点

  • 中位随访38.8个月,总缓解率82%,中位无事件生存期24个月。
  • 3年无事件生存率44%(95%CI 31-57),总生存率63%(95%CI 51-73)。
  • 输注后1年以上3/4级不良事件发生率29%,3/4级感染率未增加。

核心结论

  • 这些发现证明替沙基仑赛具有有利的长期安全性,并提示其可作为经过大量预治疗的复发/难治性B细胞急性淋巴细胞白血病儿童及年轻成人患者的治愈性治疗选择。

研究设计与样本

  • 全球II期ELIANA试验(ClinicalTrials.gov标识符:NCT02435849)的更新分析,纳入79例复发/难治性B细胞急性淋巴细胞白血病儿童及年轻成人患者,中位随访38.8个月。

主要发现

  • 总缓解率为82%。
  • 中位无事件生存期为24个月,中位总生存期未达到。
  • 3年无事件生存率为44%(95%CI 31-57),3年总生存率为63%(95%CI 51-73),多数事件发生在最初2年内。
  • 对后续治疗设删失与不设删失的估计3年无复发生存率分别为52%(95%CI 37-66)和48%(95%CI 34-60)。
  • 未报告新的或意外的长期不良事件;输注后1年以上29%的患者报告3/4级不良事件;输注后1年以上3/4级感染率未增加;患者报告生活质量改善持续至输注后36个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In the primary analysis of the global phase II ELIANA trial (ClinicalTrials.gov identifier: NCT02435849), tisagenlecleucel provided an overall remission rate of 81% in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with 59% of responders remaining relapse-free at 12 months. Here, we report an update on efficacy, safety, and patient-reported quality of life in 79 pediatric and young adult patients with R/R B-ALL following a median follow-up of 38.8 months. The overall remission rate was 82%. The median event-free survival was 24 months, and the median overall survival was not reached. Event-free survival was 44% (95% CI, 31 to 57) and overall survival was 63% (95% CI, 51 to 73) at 3 years overall (most events occur within the first 2 years). The estimated 3-year relapse-free survival with and without censoring for subsequent therapy was 52% (95% CI, 37 to 66) and 48% (95% CI, 34 to 60), respectively. No new or unexpected long-term adverse events were reported. Grade 3/4 adverse events were reported in 29% of patients > 1 year after infusion; grade 3/4 infection rate did not increase > 1 year after infusion. Patients reported improvements in quality of life up to 36 months after infusion. These findings demonstrate favorable long-term safety and suggest tisagenlecleucel as a curative treatment option for heavily pretreated pediatric and young adult patients with R/R B-ALL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Laetsch TW, Maude SL, Rives S, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022. PMID: 36399695. doi:10.1200/JCO.22.00642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。